A detailed history of Jpmorgan Chase & CO transactions in Replimune Group, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 241,275 shares of REPL stock, worth $2.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
241,275
Previous 272,133 11.34%
Holding current value
$2.9 Million
Previous $2.22 Million 2.34%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$5.01 - $9.46 $154,598 - $291,916
-30,858 Reduced 11.34%
241,275 $2.17 Million
Q1 2024

May 10, 2024

SELL
$6.87 - $9.31 $225,954 - $306,205
-32,890 Reduced 10.78%
272,133 $2.22 Million
Q4 2023

Feb 12, 2024

SELL
$6.75 - $16.18 $523,206 - $1.25 Million
-77,512 Reduced 20.26%
305,023 $2.57 Million
Q3 2023

Nov 14, 2023

BUY
$15.96 - $22.18 $1.27 Million - $1.77 Million
79,616 Added 26.28%
382,535 $6.55 Million
Q2 2023

Aug 11, 2023

BUY
$15.65 - $24.1 $2.19 Million - $3.37 Million
139,709 Added 85.6%
302,919 $7.03 Million
Q1 2023

May 18, 2023

BUY
$17.48 - $29.09 $940,214 - $1.56 Million
53,788 Added 49.16%
163,210 $2.88 Million
Q1 2023

May 11, 2023

SELL
$17.48 - $29.09 $756,359 - $1.26 Million
-43,270 Reduced 28.34%
109,422 $1.93 Million
Q4 2022

Feb 13, 2023

SELL
$17.09 - $27.91 $208,139 - $339,915
-12,179 Reduced 7.39%
152,692 $4.15 Million
Q3 2022

Nov 14, 2022

BUY
$15.6 - $21.15 $2.11 Million - $2.86 Million
135,173 Added 455.16%
164,871 $2.85 Million
Q2 2022

Aug 11, 2022

BUY
$13.32 - $19.98 $129,736 - $194,605
9,740 Added 48.8%
29,698 $519,000
Q1 2022

May 11, 2022

SELL
$15.24 - $29.75 $5.51 Million - $10.8 Million
-361,718 Reduced 94.77%
19,958 $339,000
Q4 2021

Feb 10, 2022

SELL
$25.43 - $34.25 $667,664 - $899,233
-26,255 Reduced 6.44%
381,676 $10.3 Million
Q3 2021

Nov 12, 2021

BUY
$28.98 - $39.54 $11.8 Million - $16.1 Million
407,931 New
407,931 $12.1 Million

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $593M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.